Diabetes PubMed

  • Increase font size
  • Default font size
  • Decrease font size
Home Medication Sulfonylureas Tolazamide Altering therapy of type II diabetes mellitus from insulin to tolazamide increases blood pressure in spite of weight loss

Altering therapy of type II diabetes mellitus from insulin to tolazamide increases blood pressure in spite of weight loss

Am J Hypertens. 1995 May;8(5 Pt 1):520-3.

Schmitt JK, Johns SB.

Department of Internal Medicine, Hunter Holmes McGuire Veterans Administration Medical Center, Richmond, Virginia 23249, USA.

In a retrospective study we investigated the effects of altering treatment of type II diabetes mellitus from insulin to tolazamide on weight and blood pressure. In 17 patients, weight decreased from 136 +/- 6 to 131 +/- 6% of ideal body weight (P = .01). Even though weight loss occurred, mean systolic blood pressure increased from 133 +/- 3 mm Hg to 142 +/- 4 mm Hg (P = .025). There was no difference in diastolic blood pressure on the two treatments (79 +/- 3 v 78 +/- 4 mm Hg). In an additional 10 patients whose treatment was changed from tolazamide to insulin, mean systolic blood pressure decreased from 136 +/- 1 to 124 +/- 2 mm Hg (P < .01). In spite of the potential benefits of reversal of insulin resistance and weight reduction, altering therapy of type II diabetes mellitus from insulin to tolazamide may increase blood pressure, thereby increasing cardiovascular risk.

PMID: 7662230

 

Bookmark and Share

Popular Diabetes PubMed Citations

Newsflash

Millions unite for diabetes awareness on World Diabetes Day 2010
Starting today, people from all corners of the world are uniting together for three days of celebration to put diabetes firmly in the public spotlight. World Diabetes Day is the best opportunity there is to draw attention to the silent killer that is diabetes.
 
Bristol-Myers Squibb Foundation Launches $100 Million Initiative
The Bristol-Myers Squibb Foundation announced Together on Diabetes®: Communities Uniting to Meet America's Diabetes Challenge, a 5-year, $100 million initiative to help patients living with type 2 diabetes better manage their disease beyond the doors of their doctor's office - in their homes and communities - and for the course of their disease.
 
New global survey reveals more than one in three patients fail to take insulin as prescribed
More than one in three diabetes patients skip doses or fail to take their insulin as prescribed, stating that they have done so on average three times in the last month, and 77% of physicians estimate that in reality this number could be as high as six doses*, according to the Global Attitudes of Patients and Physicians in Insulin Therapy (GAPPTM) survey, released today by Novo Nordisk.
 

Facebook Page Twitter Subscribe to Latest Diabetes PubMed facts... by Email RSS

Subscribe

Get Diabetes PubMed facts delivered by email. Enter your email address:


Delivered by FeedBurner

Who's Online

We have 7 guests online

Sponsored Links

PharmaNews.eu
PharmaNews.eu - the dynamic European pharmaceutical news engine.
www.pharmanews.eu

Advertise here